Skip to main content
Fig. 2 | Biomarker Research

Fig. 2

From: Imaging biomarkers for evaluating tumor response: RECIST and beyond

Fig. 2

Bone density changes suggest tumor response in bone metastases. A 42-year-old man was diagnosed with lung adenocarcinoma and bone metastases. Pretreatment axial CT scan in the bone window shows two osteolytic metastases (both lesions with diameters of 10 mm) (white arrows) in thoracic vertebrae. B, C The osseous lesions have not significantly changed in the sum of longest diameters according to RECIST 1.1 but show osteosclerotic reaction (white arrows) in 6 months (B) and 10 months (C) after targeted therapy with afatinib, an epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitor (TKI), representing good response. D, E Skeletal scintigraphy shows significantly decreased uptake of radiotracer after comparison between pretreatment (D) and posttreatment (E) images, which confirmed good therapeutic response

Back to article page